EyePoint, Inc. Common Stock
EYPTEyePoint Pharmaceuticals, Inc. (EYPT) is a pharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in treatments for retinal diseases, uveitis, and other ocular conditions, leveraging its expertise in drug delivery and molecular innovation to address unmet medical needs in ophthalmology.
Company News
EyePoint, Inc. granted non-statutory stock options to three new employees as inducement awards on June 15, 2026. The company granted options to purchase 39,700 shares at an exercise price of $12.08 per share with a ten-year term and four-year vesting schedule. The grants were approved by the Compensation Committee in accordance with NASDAQ regula...
EyePoint, Inc. (EYPT) announced participation in three upcoming healthcare conferences in May-June 2026. The company also reported a third consecutive positive Data Safety Monitoring Committee (DSMC) recommendation for its Phase 3 wet AMD trials of DURAVYUâ„¢, with topline data expected in mid-2026. The trials continue to show a favorable safety ...
EyePoint announced Q1 2026 financial results with $223 million in cash runway extending into Q4 2027. The company's lead product DURAVYU is progressing through Phase 3 trials for wet AMD and DME, with topline data expected beginning mid-2026 for wet AMD and Q4 2027 for DME. However, net revenue declined significantly to $0.7 million from $24.5 mi...
Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage th...
EyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to purchase 20,000 shares of common stock to six new employees as inducement awards on March 13, 2026, with an exercise price of $13.20 per share. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for w...
